41373-96-0

Basic information

• Product Name: 3,6-dichloro-4-phenyl-pyridazine
• CAS NO: 41373-96-0
• Molecular Formula: C₁₀H₆Cl₂N₂
• Molecular Weight: 225.07404
• Mol File: 41373-96-0.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 384.3°C at 760 mmHg
• Flash Point: 218.3°C
• Appearance: /
• Density: 1.363g/cm³
• Vapor Pressure: 9.12E-06mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: 3,6-dichloro-4-phenyl-pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-dichloro-4-phenyl-pyridazine(41373-96-0)
• EPA Substance Registry System: 3,6-dichloro-4-phenyl-pyridazine(41373-96-0)

Safety Data

• Hazardous Substances Data: 41373-96-0(Hazardous Substances Data)

Usage

General Description

3,6-dichloro-4-phenyl-pyridazine is a chemical compound with the molecular formula C10H6Cl2N2. It is a pyridazine derivative that contains two chlorine atoms and a phenyl group attached to the pyridazine ring. 3,6-dichloro-4-phenyl-pyridazine is mainly used as a building block for the synthesis of various pharmaceuticals, agrochemicals, and materials. It can also be used as an intermediate in the production of dyes and other organic compounds. Additionally, 3,6-dichloro-4-phenyl-pyridazine has potential applications in the field of medicinal chemistry and drug discovery due to its structural features and biological activity. However, it is important to handle this compound with caution as it may pose health and environmental risks if not properly managed.

InChI:InChI=1/C10H6Cl2N2/c11-9-6-8(10(12)14-13-9)7-4-2-1-3-5-7/h1-6H

Upstream product

• 41373-90-4 4-Phenyl-3,6-dioxo-1,2,3,6-tetrahydropyridazine 
• 453511-76-7 4-phenylpyridazin-3,6-dione 
• 41373-90-4 4-phenylpyridazine-3,6-diol 
• 36122-35-7 2-phenylmaleic anhydride 
• 141-30-0 3,6-dichlorpyridazine 
• 98-80-6 phenylboronic acid 
• 591-50-4 iodobenzene 
• 16110-98-8 (Z)-2-phenylbut-2-enedioic acid 

Downstream Products

• 92184-43-5 4-phenylpyridazine 
• 36122-35-7 2-phenylmaleic anhydride 
• 869487-49-0 6-chloro-5-phenyl-3-pyridazinylhydrazine 
• 844875-95-2 3-chloro-4-phenyl-6-(morpholin-4-yl)-pyridazine 
• 902456-34-2 4-phenyl-6-(morpholin-4-yl)-3(2H)-pyridazinone 
• 902456-40-0 3-[4-phenyl-6-(morpholin-4-yl)-3(2H)-pyridazinon-2-yl]propanenitrile 
• 902456-38-6 2-[4-phenyl-6-(morpholin-4-yl)-3(2H)-pyridazinon-2-yl]acetic acid 
• 902456-36-4 ethyl 2-[4-phenyl-6-(morpholin-4-yl)-3(2H)-pyridazinon-2-yl]acetate 
• 902456-42-2 3-[4-phenyl-6-(morpholin-4-yl)-3(2H)-pyridazinon-2-yl]propanoic acid 
• 869487-50-3 6-benzoylhydrazino-3-chloro-4-phenylpyridazine 
• 54248-88-3 3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine-6-ylchloride 
• 868280-49-3 N,N-dimethyl-6-chloro-5-phenylpyridazin-3-amine 
• 868280-53-9 3-chloro-6-methoxy-4-phenylpyridazine 
• 868280-55-1 3-chloro-4-phenyl-6-pyridin-3-ylpyridazine 

Relevant articles and documents

Pyridazinone derivative and application thereof

The invention provides a pyridazinone derivative and an application thereof, the pyridazinone derivative with the structure shown in the formula (I) provided by the invention has good activity as a thyroid hormone beta receptor agonist by selecting a specific modification group. The compound can be used for treating and/or preventing diseases caused by thyroid hormone regulation.

Silver-Catalyzed Minisci Reactions Using Selectfluor as a Mild Oxidant

A new method for silver-catalyzed Minisci reactions using Selectfluor as a mild oxidant is reported. Heteroarenes and quinones both participate in radical C-H alkylation and arylation from a variety of carboxylic and boronic acid radical precursors. Several oxidatively sensitive and highly reactive radical species are successful, providing structures that are challenging to access by other means.

Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors

The design and synthesis of pyridazinone and phthalazinone derivatives are described. Newly synthesized compounds were tested on a panel of four kinases in order to evaluate their activity and potential selectivity. In addition, the promising compounds were tested on four cancer cell lines to examine cytotoxic effects. The compounds inhibited DYRK1A and GSK3 with different activity. SAR analysis and docking calculations were carried out to aid in the interpretation of the results. Taken together, our findings suggest that pyridazinone and phthalazinone scaffolds are interesting starting points for design of potent GSK3 and DYRK1A inhibitors.